Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A phase 3 trial finds vosoritide significantly boosts growth in kids with hypochondroplasia. Children receiving the once-daily injectable grew 2.33 cm/year more than those on placebo, with quality of life scores also improving. There are currently no FDA-approved treatments for this condition, making these results a potential breakthrough.
Children with hypochondroplasia — a genetic skeletal condition causing short stature — may soon have their first approved treatment. A phase 3 trial (CANOPY HCH-3) published in NEJM Evidence found that once-daily injectable vosoritide (Voxzogo, BioMarin) significantly outperformed placebo across multiple growth measures in 81 children aged 3–17 years over one year. Vosoritide is already FDA-approved for achondroplasia, but no approved therapy currently exists for hypochondroplasia.
Beyond height, children on vosoritide also showed greater gains in arm span and meaningful improvements in quality of life scores, suggesting the drug's benefits extend beyond linear growth. The safety profile was reassuring — no serious adverse events were linked to vosoritide, and no participants discontinued due to side effects.
By the Numbers:
Why it matters: Hypochondroplasia has no FDA-approved treatments, leaving families with limited options. These results could pave the way for the first precision medicine approval for this condition, with researchers noting that sustained effects could translate to meaningful gains in height, body proportions, and long-term function.
